Human Alpha-Galactosidase A/GLA PharmaGenie ELISA Kit (SBRS0236)

This quantitative immunoassay from Assay Genie targets human Alpha-Galactosidase A (GLA), the lysosomal hydrolase whose functional deficit drives Fabry disease, an X-linked lysosomal storage disorder characterized by globotriaosylceramide (Gb3) substrate accumulation. The kit supports research into enzyme replacement therapy efficacy, substrate clearance mechanisms, and biomarker profiling in patient-derived samples.

Reagents are validated across cell culture supernatant, plasma, and serum specimens and accommodate both in vitro cell-based studies and translational clinical sample analysis. Readout is colorimetric, performed on a standard microplate reader, and the kit is supplied as a 96-assay research-use-only package.

Calibrated specifically against the human GLA sequence, the assay is intended for studies where species specificity matters, such as Fabry patient fibroblast profiling, gene therapy expression monitoring, and GLA enzyme activity modulator screening. Researchers working on lyso-Gb3 biomarker panels or comparing wild-type versus mutant GLA expression in heterologous systems will find the human-specific calibration useful for quantitative interpretation.